T-Cell study funded

Article

The National Institutes of Health (NIH) National Cancer Institute has granted $124,000 to Aastrom Biosciences, Inc. to develop an immunotherapeutic treatment of malignant melanoma using AastromReplicell System cell production technology.

Related Videos
Related Content

Combination Surgery Plus Adalimumab More Clincially Effective in HS Than Adalimumab Alone

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Pointers With Portela: Treating Fungal Acne

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

Combination Surgery Plus Adalimumab More Clincially Effective in HS Than Adalimumab Alone

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Pointers With Portela: Treating Fungal Acne

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

Combination Surgery Plus Adalimumab More Clincially Effective in HS Than Adalimumab Alone

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Pointers With Portela: Treating Fungal Acne

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023
© 2023 MJH Life Sciences

All rights reserved.